ICUI vs OMCL: Which Is the Better Buy in 2026?
Last updated August 2026
Short answer
ICUI is the larger of the two ($4.64B market cap): the incumbent the market prices for continued execution (19.55x forward earnings, beta 0.75). OMCL is the smaller challenger ($1.61B), cheaper on forward earnings (16.36x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.
ICUI vs OMCL: the tie-breaker metrics
Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | ICUI | OMCL | What it tells you |
|---|---|---|---|
| Market cap | $4.64B | $1.61B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 19.55 | 16.36 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Trailing P/E | 99.88 | 42.11 | Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price. |
| Beta | 0.75 | 0.97 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 94% of range | 24% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 2.20 | 1.28 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Reading it: OMCL is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.
Before you buy: how ICUI and OMCL affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ICUI and OMCL share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ICUI and OMCL exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does ICU Medical (ICUI) do?
ICU Medical makes the plumbing of hospital drug delivery. Its Consumables segment sells IV sets, needle-free connectors (the CLAVE family it has built its reputation on), oncology and vascular access products, and tracheostomy devices. Infusion Systems sells the large volume, syringe and ambulatory pumps that push those fluids, including the Plum Duo and Plum Solo platforms plus the LifeShield safety software layer and the CADD and Medfusion pumps inherited from Smiths Medical. Vital Care is the catch-all for temperature management, respiratory, cardiac monitoring and the IV solutions business, most of which now sits inside Otsuka ICU Medical LLC, the joint venture formed in May 2025 when ICU sold 60% of IV Solutions to Otsuka Pharmaceutical Factory America and kept a 40% stake. Revenue for full year 2025 was about $2.23 billion, down roughly 6% on a reported basis almost entirely because of that deconsolidation, with Consumables at about $1.11 billion, Infusion Systems at about $684 million and Vital Care at about $438 million.
What does Omnicell (OMCL) do?
Omnicell, Inc. (NASDAQ: OMCL) is a healthcare-technology company that builds medication-management and pharmacy-automation systems for hospitals, health systems, retail and specialty pharmacies, and other care settings. Its core products include automated dispensing cabinets (the XT and XR series), central-pharmacy robotics, IV compounding automation, and a growing layer of cloud software and services branded around what the company calls the Autonomous Pharmacy. Omnicell earns money from product sales (the hardware and installed systems) and from a rising base of recurring service and subscription revenue, including its Advanced Services and technician-enabled offerings, and it tracks annual recurring revenue (ARR) and product bookings as key operating metrics.
ICUI vs OMCL: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- ICUI drivers: The Infusion Systems replacement cycle; Gross margin recovery.
- OMCL drivers: Shift toward recurring software and services; Large installed base and replacement cycle.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Regulatory and quality exposure is the most specific risk. For OMCL, omnicell's product revenue depends heavily on hospital and health-system capital budgets, which are cyclical and can be cut quickly when providers face financial pressure, making bookings and revenue lumpy.
ICUI or OMCL: which should you pick?
Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ICUI if you believe its drivers more; OMCL if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ICUI and OMCL guides.
ICUI vs OMCL: the full fundamentals
ICUI. At roughly $187 per share, ICUI trades near 21 times the midpoint of its guided adjusted EPS and around 13 times enterprise value to guided adjusted EBITDA, which is a discount to large-cap medical device peers and reflects the leverage plus the unfinished integration. The gap between GAAP and adjusted numbers is unusually wide here, with FY2026 GAAP EPS guided to roughly $1.03 to $1.74 originally and raised to roughly $2.89 to $3.29, because acquisition amortization, restructuring and integration costs are excluded from the adjusted figures. ICU Medical pays no dividend and directs its cash toward debt repayment instead.
OMCL. Omnicell trades around $43 per share for a market capitalization near $1.96 billion as of July 2026, with a wide 52-week range that reflects how sensitive the stock is to bookings and margin trends. The trailing GAAP P/E has been very high (around 97) because GAAP earnings have been depressed, while normalized or forward multiples on non-GAAP EPS are far lower (Morningstar cited a normalized P/E near 22). That gap between GAAP and non-GAAP earnings is central to how different investors value the name.
Headline figures (approximate, August 2026): ICUI shows revenue (fy2025) ~$2.23 billion, q2 2026 revenue ~$552 million, ~6% organic growth, adjusted ebitda (fy2026 guide) ~$415 million to ~$435 million, adjusted eps (fy2026 guide) ~$8.60 to ~$9.00; OMCL shows revenue (fy2025) ~$1.185 billion (up ~7%), non-gaap ebitda (fy2025) ~$140 million, revenue (q1 2026) ~$310 million (up ~15% YoY), non-gaap eps (q1 2026) ~$0.55 (vs ~$0.26 a year earlier).
The bottom line: ICUI vs OMCL
ICUI and OMCL are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ICUI and OMCL exposure against your real portfolio. It is not an investment adviser.
Wondering how ICUI or OMCL fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Investing in ICU Medical with AI
Connect the broker you already use and ask Walnut's AI how ICUI fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
What is the difference between ICUI and OMCL?
+
ICU Medical makes the plumbing of hospital drug delivery. Omnicell, Inc. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is ICUI or OMCL the better stock?
+
Neither is universally better. ICUI is the larger incumbent; OMCL is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, ICUI or OMCL?
+
On forward P/E (as of August 2026), ICUI trades at 19.55x and OMCL at 16.36x, so OMCL is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both ICUI and OMCL?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of ICUI vs OMCL?
+
ICUI: Regulatory and quality exposure is the most specific risk. The FDA issued a warning letter in April 2025 stating that ICU Medical made changes to the Medfusion Model 4000 syringe pump and the CADD Solis VIP ambulatory pump without the required premarket submissions, and that letter followed a run of recalls dating back to the Smiths integration, so remediation costs and any further enforcement action remain open items. Several plaintiff law firms announced securities fraud investigations after that disclosure, and while ICU Medical describes its litigation as ordinary course, headline risk on this front has not gone away. Operationally, tariffs are running at an estimated $30 million to $40 million annually, yen weakness has been a multi-year currency headwind, and hospital capital budgets can defer pump purchases in a downturn. Financially, leverage near 2.3 times leaves less room for a stumble than a debt-free peer would have, and the gap between guided GAAP EPS of roughly $2.89 to $3.29 and adjusted EPS of roughly $8.60 to $9.00 is large enough that how an investor treats amortization and restructuring charges materially changes what the stock looks like. OMCL: Omnicell's product revenue depends heavily on hospital and health-system capital budgets, which are cyclical and can be cut quickly when providers face financial pressure, making bookings and revenue lumpy. It competes against larger and better-capitalized rivals, most notably BD (Becton Dickinson) with its Pyxis dispensing line, along with Baxter, Swisslog, and other automation vendors, which can pressure pricing and market share. The company's GAAP profitability has at times been thin relative to its share price, so a large gap between GAAP and non-GAAP earnings and a high trailing P/E leave little room for execution missteps. Long installation and implementation cycles, customer concentration among big health systems, and integration risk from acquisitions add operational uncertainty. Broader healthcare-policy shifts, reimbursement pressure, supply-chain costs, and any product-reliability or regulatory issues around medication safety could also weigh on results.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell ICUI or OMCL; figures are approximate and dated (as of August 2026). Verify current data before investing.